-
Security Type
-
Crowd SAFE
-
Min Investment
-
$500
-
Offering Date
-
March 09, 2021
-
Expected Close Date
-
September 29, 2021
-
Target Raise
-
$50.00K-$1.07M
-
IPO Date
-
2021-07-15
-
Security Price
-
$1
Company Description
Eysz is developing an AI-driven digital health solution - to measure neurological progression, intervention efficacy, and side effects and provide the data clinicians need to assist them in developing a personalized care plan for their patients with Epilepsy.
Key Deal Facts
$1.5M in funding including UCB Pharma, Plug and Play Ventures
$800K in grant funding: NIH, NSF, CTIP, Greenwich Biosciences
Meeting with FDA confirming regulatory pathway completed
Multi-center clinical study (DASEY) enrolling to refine algorithm
>$5B global market opportunity, $1.7B in the US
Multi-Awards: Epilepsy Foundation Shark Tank (1st), International Society for Optics and Photonics (3rd), Berkeley Haas Healthcare (1st)
Management Team / Advisory Board Bios
Rachel Kuperman, MD, Founder & CEO
Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland
Jit Sarkar, PhD Co-Founder
Leads the algorithm development for Eysz solution. He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.
Parth Amin, Co-Founder
Leads our Product Development efforts and GTM Strategy. Brings 15+ Years Medical Device Experience in Product and Project Management, Product Launch, and Alliances having worked at Siemens Healthineers, Varian, and Omnicell.